{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:17:03Z","timestamp":1792081023885,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":82,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.rmcr.2021.101405","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T14:15:08Z","timestamp":1617200108000},"page":"101405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-1517","authenticated-orcid":false,"given":"Tomoyo","family":"Oguri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Sasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reishi","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemichi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-895X","authenticated-orcid":false,"given":"Ryohei","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmcr.2021.101405_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.rmcr.2021.101405_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12943-020-01200-x","article-title":"The biomarkers of hyperprogressive disease in PD-1\/PD-L1 blockage therapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Canc."},{"key":"10.1016\/j.rmcr.2021.101405_bib3","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.rmcr.2021.101405_bib4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/CAD.0000000000000837","article-title":"Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer","volume":"30","author":"Bosch-Barrera","year":"2019","journal-title":"Anti Canc. Drugs"},{"key":"10.1016\/j.rmcr.2021.101405_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.rmcr.2021.101405_bib7","first-page":"385","article-title":"Novel patterns of response under immunotherapy, Ann","volume":"30","author":"Borcoman","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib8","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"8","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib9","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non\u2013small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.rmcr.2021.101405_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","article-title":"Antibody\u2013Fc\/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non\u2013small cell lung cancer subsequent to PD-1\/PD-L1 blockade","volume":"25","author":"Lo Russo","year":"2019","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.rmcr.2021.101405_bib11","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.rmcr.2021.101405_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR- mutated non\u2013small cell lung cancer\u2014a meta-Analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.rmcr.2021.101405_bib14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013Selected patients with NSCLC","volume":"14","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmcr.2021.101405_bib15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.rmcr.2021.101405_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0169-5002(01)00224-0","article-title":"Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma","volume":"34","author":"Chang","year":"2001","journal-title":"Lung Canc."},{"key":"10.1016\/j.rmcr.2021.101405_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JTO.0b013e3181ce3e3c","article-title":"Pulmonary Pleomorphic Carcinoma: a clinicopathological study including EGFR mutation analysis","volume":"5","author":"Kaira","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920915983","article-title":"Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)","volume":"12","author":"Gelsomino","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.rmcr.2021.101405_bib19","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1111\/1759-7714.13594","article-title":"Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"10","author":"Choi","year":"2020","journal-title":"Thorac. Cancer."},{"key":"10.1016\/j.rmcr.2021.101405_bib20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007121000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:04:21Z","timestamp":1761959061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007121000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"alternative-id":["S2213007121000678"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101405","relation":{},"ISSN":["2213-0071"],"issn-type":[{"value":"2213-0071","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2021.101405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101405"}}